Monday, January 19, 2009

The Bush Vaccine Initiatives

Geez.... and I thought the Bush Administration was so anti-science, anti-research; have a look at this article describing the upcoming deflation of the vaccine sector:

"Coordinated by the Office of Biomedical Advanced Research & Development Authority (BARDA) within the Department of Health & Human Services, this influx of money during the Bush years has re-energized the flu vaccine business and brought in large new players where there previously there had been a slow exodus of firms. Three major companies and one significant independent vaccine business have taken advantage of the flu funding to join the US market: GlaxoSmithKline (through imports and the purchase of ID Biomedical in Canada), Novartis (through Chiron), AstraZeneca (through Medimmune) and CSL (joining the US market from Australia). Are the manufacturing and commercial development subsidies that the vaccine companies learned to count on from the Bush Administration likely to continue? Probably not; but they may be replaced by a different, and more timely, form of incentive – enhanced government-stimulated markets for vaccine products." Cole Werble, RPM First Take, January 19, 2009.

So instead of continuing R&D and infrastructure development to make vaccines more financially palatable to the Pharma industry, the Obamanoid will expand accessibility to the target populations for conventional vaccines. Interesting, but wasn't that the exact market that led to the mass Pharma exits pre-9/11?


Post a Comment

<< Home